PHILADELPHIA, July 27 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP - News; NASDAQ: SHPGY - News; TSX: SHQ - News) announced today that VYVANSE (lisdexamfetamine dimesylate), a new once-daily medication approved to treat the symptoms of Attention Deficit Hyperactivity Disorder (ADHD), is now available in U.S. pharmacies nationwide. In a clinical study, VYVANSE provided consistent ADHD symptom control throughout the day based upon parent reports in the morning (approximately 10am), afternoon (approximately 2pm), and early evening (approximately 6pm). This may be of interest to mothers of children with ADHD based on a recent survey of 121 mothers of ADHD children aged 6 to 12 years, in which 60 percent of mothers reported that their child’s ADHD medication stopped working before 6pm and 40 percent reported that their child’s ADHD medication stopped working before 4pm.
